AKthelia awarded a RANNÍS grant

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy
Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis
AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES
eliminating the need for prophylactiC antibiotics
reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis

HOME
News
AKthelia awarded a RANNÍS grant

AKthelia awarded a RANNÍS grant

Novel wound healing approach

June 1, 2021

Akathelia together with co-founder prof. Guðmundur Hrafn Guðmundsson has been awarded a RANNÍS grant from the Applied Research projects (Hagnýt rannsóknarverkefni) for the initial development of a novel wound healing technology. The total grant amounts to 45 mISK over three years.

Febrile neutropenia is a common, life-threatening complication of chemotherapy

Gut barrier Injury and Neutrophil depletion puts patients at risk for bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT BACTERAEMIA BY STRENGTHENING INNATE GUT BARRIER DEFENSES

eliminating the need for prophylactiC antibiotics

reducing risk of serious adverse events, antimicrobial resistance and microbiome dysbiosis

AKthelia awarded a RANNÍS grant

Novel wound healing approach

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy

Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES

reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis